B

Beeline Medicines

Clinical-stage biotech developing precision autoimmune therapies

Senior Director - Regulatory Affairs CMC

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • Advanced degree (PhD, MS, or PharmD) in organic chemistry, pharmaceutical sciences, analytical chemistry, or a related small molecule-relevant discipline is strongly preferred.
  • A minimum of 12+ years of CMC regulatory affairs experience in the pharmaceutical or biotech industry is preferred.
  • Hands-on small molecule CMC regulatory experience is required.
  • Experience with biologics CMC regulatory strategy, including monoclonal antibodies and recombinant proteins, is highly preferred but not required.
  • Deep and comprehensive expertise in small molecule CMC regulatory strategy, including drug substance (API) synthesis and control, drug product formulation and manufacturing, and analytical method development and validation for oral, parenteral, and other dosage forms.
  • Extensive experience authoring and overseeing small molecule CMC sections of global regulatory submissions, including INDs/CTAs, NDAs, MAAs, and post-approval supplements and variations in ICH CTD/eCTD format.
  • A demonstrated track record of leading FDA and EMA CMC-focused Health Authority meetings, including preparing briefing documents and strategically managing written responses to CMC deficiency letters.
  • Comprehensive knowledge of ICH Q8/Q9/Q10/Q11/Q12 guidelines, FDA small molecule CMC guidance documents such as SUPAC, process validation, and container closure, and EMA quality guidance applicable to small molecule chemical entities.
  • Proven experience managing CMC regulatory aspects of technology transfer, new CMO qualification, and site-change regulatory filing strategies for small molecule programs.
  • Strong command of post-approval CMC change management regulations, including SUPAC categories, PAS/CBE filing requirements, and ex-US variation frameworks.
  • Demonstrated ability to lead and develop cross-functional teams in a fast-paced, resource-constrained biotech or pharmaceutical environment and foster accountability, inclusion, and continuous learning.
  • A proven track record of influencing without authority across organizational boundaries, driving alignment among senior stakeholders, and building consensus on complex regulatory or scientific priorities.
  • Experience navigating organizational ambiguity and change, defining structure, establishing priorities, and scaling functional capabilities in alignment with evolving corporate strategy.
  • Exceptional written and verbal communication skills and the ability to translate complex regulatory, scientific, or operational content for executive leadership, Health Authorities, and cross-functional partners.
  • Skill in preparing and delivering presentations, briefing documents, and strategic updates to cross-functional leadership teams, board-level stakeholders, and external regulatory agencies.
  • Ability to facilitate productive dialogue in high-stakes meetings, Health Authority interactions, and multi-party collaborations while balancing clarity, diplomacy, and scientific precision.

Responsibilities

  • Develop and lead CMC regulatory strategy for all small molecule assets in the I&I portfolio, from IND/CTA through NDA filing, including post-approval lifecycle management and drug substance and drug product labeling strategy.
  • Author, review, and oversee CMC sections of global regulatory submissions in ICH CTD format, including INDs, CTAs, NDAs, MAAs, Type II variations, and supplements, ensuring quality, completeness, and regulatory defensibility.
  • Serve as the primary regulatory authority and strategic partner for small molecule Technical Development, Process Chemistry, Analytical Development, Formulation Sciences, and Quality functions on CMC regulatory matters.
  • Lead Health Authority interactions on small molecule CMC topics, including FDA Type B and Type C meetings, EMA Scientific Advice meetings, and written responses to CMC deficiency letters and information requests from global regulatory agencies.
  • Interpret FDA, EMA, and ICH CMC guidance applicable to small molecules, including ICH Q8, Q9, Q10, Q11, and Q12, and advise development teams on regulatory acceptability of design space, process validation, and control strategy.
  • Lead post-approval CMC change management strategy for small molecule programs, including SUPAC assessments, Prior Approval Supplements (PAS), Changes Being Effected (CBE) filings, and ex-US variation submissions.
  • Oversee regulatory aspects of small molecule technology transfers, including new CMO onboarding, site-to-site comparability, and associated regulatory filing updates.
  • Establish and maintain CMC regulatory SOPs, templates, and document-management workflows for small molecule programs, ensuring compliance with ICH CTD, eCTD, and applicable electronic submission requirements.
  • Contribute CMC regulatory risk assessments and readiness analyses to regulatory due diligence evaluations of small molecule licensing candidates or acquisition targets.
  • Track CMC regulatory deliverables and submission timelines across small molecule programs, proactively identifying dependencies, risks, and upcoming milestones to keep cross-functional teams aligned and submission-ready.
  • Partner within the CMC team by attending key technical meetings, engaging daily with Process Development, Analytical, Manufacturing Sciences, Drug Supply, and Quality colleagues, and translating regulatory strategy into practical guidance that enables informed decisions and advances programs.
  • Proactively seek information, build relationships across the CMC organization, and use initiative and resourcefulness to execute CMC regulatory responsibilities, earn trust, and remove barriers.
  • Perform other duties and responsibilities as assigned.

Desired Qualifications

  • Experience with biologics CMC regulatory strategy, including monoclonal antibodies and recombinant proteins, is highly preferred but not required.
  • A minimum of 12+ years of CMC regulatory affairs experience in the pharmaceutical or biotech industry is preferred.

About the Company

Beeline Medicines

Clinical-stage biotech developing precision autoimmune therapies

Beeline Medicines focuses on precision therapies for autoimmune and inflammatory diseases, advancing a portfolio of in-licensed programs from Bristol Myers Squibb with strong backing from Bain Capital. Its lead, afimetoran, is an oral TLR7/8 inhibitor for lupus, with lomedeucitinib as an allosteric TYK2 inhibitor and two IND-stage biologics targeting IL-18 and IL-10 pathways to modulate immune signaling. The company differentiates itself by combining externally sourced programs with a leadership team experienced in drug development and commercialization, pursuing multiple mechanism-driven candidates rather than a single modality, supported by substantial early funding. Its goal is to move its clinical-stage therapies toward pivotal trials and bring targeted immune-modulating treatments to patients, beginning with completing Phase 2 for afimetoran in late 2026 and following with a pivotal program.

Company size
51-200
Company stage
Series A
Total funding
$426.3M
Headquarters
Stamford, CT
Founded
2025

Recently Posted Jobs

Explore more opportunities at Beeline Medicines

See more jobs